Sophia Genetics, a Switzerland-based specialist in data-driven medicine, has raised $13.75m in a series B round led by Invoke Capital that also included telecommunications company Swisscom and Endeavour Vision.
Apart from the cash injection, Sophia gains access to Invoke’s portfolio company Genalys, which uses big data mathematics to analyse genomic information.
Spun out of the Federal Institute of Technology Lausanne in 2011, Sophia’s technology makes it possible to diagnose genetic diseases and the DNA of cancer tumours through a combination of next generation sequencing and highly accurate and scalable predictive algorithms.
Sophia and Genalys hope to use each other’s expertise to improve the technology, which is currently patent-pending, even further.
Sophia Genetics previously raised $2.8m in 2013 from undisclosed investors. The company is ahead of its competition in that it is already fully compliant with European data privacy laws.
Jurgi Camblong, CEO of Sophia Genetics, said: “This new funding will allow us to move faster into European markets. Invoke Capital in particular provides a degree of expertise in data security in cloud and in scalability that will strengthen our genetic sequencing data banking offering immediately.”